Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, and its subsidiary Adimune(TM) Inc. announced a clinical trial agreement with Mayo Clinic. The clinical trial, which is designed to advance clinical studies targeting autoimmune diseases of the central nervous system (“CNS”), is expected to begin this year with an estimated 10 to 15 patients, some of whom may also suffer from type-1 diabetes; the initial focus of the study will be on the autoimmune disease Stiff Person Syndrome (“SPS”). According to the announcement, Adimune, which was created to lead Aditxt’s immune modulation therapeutic programs, has almost completed its preclinical package for the immunotherapy clinical study drug candidate ADI-100. The company noted that it has been working to launch ADI(TM)-100, its first immune modulation product candidate, for more than a year; the company has been targeting clinical trials to demonstrate its safety and indications of efficacy. “We are extremely pleased about having the opportunity to work with Mayo Clinic on trying to restore immune tolerance in patients suffering from devastating progressive autoimmune central nervous system disorders,” said Adimune co-CEO Dr. Joachim Friedrich Kapp in the press release. “The collaboration will include both preclinical and clinical studies and builds on Adimune’s current efforts to advance the full preclinical and clinical programs of ADI-100. We believe that the preclinical studies will help us to expand on the understanding of the technology, specifically the mechanism of action which induces antigen-specific immune tolerance without impairing the responsiveness of the immune system to fight infections and cancers.”
To view the full press release, visit https://ibn.fm/WnYBv
About Aditxt Inc.
Aditxt is a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system. The company’s mission of “Making Promising Innovations Possible, Together” is defined by its growing ecosystem of research institutions, global industry partners and shareholders that inform and inspire. Aditxt’s diverse innovation portfolio includes Adimune Inc.(TM), aimed at developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir Inc.(TM), focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta Inc.(TM), which intends to offer personalized immune monitoring for a wide range of health conditions, including hereditary cancer, wounds and cardiomyopathy. For more information, please visit www.Aditxt.com and www.AditxtScore.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
